Ursodeoxycholic Acid Dosing for Small Gallbladder Stones
For an adult with a small gallbladder stone, prescribe ursodeoxycholic acid at 8-10 mg/kg/day divided into 2-3 doses, continued for up to 2 years or until complete stone dissolution is confirmed on repeat imaging.
Dosing Regimen
The FDA-approved dosing for gallstone dissolution is 8-10 mg/kg/day given in 2 or 3 divided doses 1. This represents the optimal therapeutic dose based on clinical trial data showing the best balance of efficacy and tolerability 2.
Key Dosing Points:
- Minimum effective dose: Research demonstrates that at least 8-10 mg/kg/day is required for consistent bile desaturation and therapeutic effect 3, 4
- Higher doses (>10 mg/kg/day) do not significantly improve dissolution rates and may increase side effects 3
- Single daily dosing (450 mg at bedtime) has shown comparable efficacy to divided doses for stones ≤15 mm 5, though FDA labeling recommends divided dosing
Treatment Duration
Primary treatment period: Continue therapy for up to 2 years 2, 1. The duration depends on stone response:
Monitoring Algorithm:
Obtain ultrasound at 6 months to assess response 1
- If partial or complete dissolution is seen → continue therapy
- If no dissolution by 12 months → likelihood of success is greatly reduced; consider discontinuing 1
If stones appear dissolved → continue UDCA and confirm dissolution on repeat ultrasound within 1-3 months 1
Most successful cases show partial dissolution within 6 months (>70% chance of eventual complete dissolution) 1
Patient Selection Criteria
UDCA works best for:
- Small stones (<15-20 mm diameter) - stones <5 mm have 81-85% dissolution rates 1, 5
- Radiolucent (cholesterol) stones - calcified stones rarely dissolve 2, 1
- Functioning gallbladder (visualizes on imaging) 2
- "Floating" stones (high cholesterol content) - up to 50% dissolution rate 1
Critical Pitfalls
⚠️ Discontinue therapy if:
- Gallbladder becomes non-visualizing during treatment (predicts failure) 1
- No partial dissolution by 12 months 1
- Stone calcification develops during treatment 2, 1
⚠️ Stone recurrence: Occurs in 30-50% of patients within 2-5 years after successful dissolution 1. Serial ultrasound monitoring is essential post-treatment.
Limitations of Medical Therapy
The guidelines emphasize that only 20% of cholecystectomy candidates are suitable for UDCA therapy 2. Medical dissolution:
- Does not prevent stone recurrence
- Does not prevent gallbladder cancer
- Requires daily medication for up to 2 years
- Has limited efficacy compared to surgery 2
Complete dissolution rates: Approximately 30% in unselected patients with appropriate stones treated for up to 2 years 1, but can reach 50-85% in ideal candidates (small, floating stones) 1, 5.
Safety Profile
UDCA is well-tolerated with minimal side effects: